Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFT-T2D: Luseogliflozin Addition After Tirzepatide Weight-Loss Plateau in Type 2 Diabetes
jRCT1041250186Recruiting
- Sponsor
- Kanazawa Medical University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kanazawa Medical University. Primary endpoints: Change in body weight and Change in HbA1c. Started Feb 2026; status: recruiting.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1041250186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041250186.